SSAA09E2 is a novel inhibitor of SARS-CoV replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2)

ATV006 is a potent, orally active antiviral agent and ester prodrugs of GS-441524. ATV006 inhibits the replication of SARS-CoV-2 and its variants. ATV006 can be used for SARS-CoV-2 research.

SB27012 (SB 27012) is a small molecule PPI inhibitor of the Spike RBD-ACE2 interaction (IC50=7.7 uM in ELISA assays), binds ACE2 (Kd=210 nM) without affecting ACE2 enzymatic activity.

A potent HCV NS5B RNA polymerase inhibitor.

NACE2i is a cell permeable, specific and selective peptide inhibitor of nuclear ACE2, inhibits binding between IMP1α and ACE2 and SARS-CoV-2 viral replication. NACE2i specifically targets nuclear ACE2 and not other nuclear proteins targeted by the importin pathway. NACE2i has no impact on ACE2 enzymatic activity. NACE2i prevents inflammation and macrophage infiltration, and increases NK cell infiltration in bronchioles. NACE2i treatment increases the levels of the active histone mark, H3K27ac, restores host translation in infected hamster bronchiolar cells, and leads to an enrichment in methylated ACE2 in hamster bronchioles and lung macrophages. NACE2i has a dual mode of action: suppressing the lethal inflammation in severe COVID-19 and inhibiting viral replication by restoring host translation of anti-viral cytokines.

NBCoV2 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=13.8 nM, SARS-CoV-2 IC50=22.8 nM, MERS-CoV IC50=77 nM, cell-based single-cycle assays). NBCoV2 also has potent antiviral activity against all mutant pseudoviruses carrying single-, double-, or triple-mutations featured in the B.1.1.7 UK, B.1.351 RSA, and B.1.617.2 Delta variants (IC50=30-80 nM). NBCoV2 completely preventing the induction of any virus-induced CPE (IC100=1.25 uM, SARS-CoV-2 (US_WA-1/2020)). NBCoV2 bind to the S2 subdomain of the SARS-CoV-2 trimer, thus, inhibits the fusion of CoVs with the cell membran, and is specific for the SARS-CoV-2 S protein.

Zevotrelvir (Compound 52) is a coronavirus inhibitor with IC50 ranges of <0.1 μM and <0.1mM for 229E hCoV and SARS-CoV-23C-like (3CL) proteases, respectively. Zevotrelvir has the potential to study viral infections.

NSC89641 inhibits MERS-CoV Mpro, with an IC50 value < 3.5 μM. NSC89641 exhibits the high inhibitory potency against SARS-CoV-2 Mpro enzymatic activity, with an IC50 of 3.05 μM.

Z8539_0072 is a potent SARS-CoV-2 macrodomain inhibitor that binds to the NSP3 macrodomain of SARS-CoV-2 (Mac1) with IC50 of 460 nM.

Z222979552 is a small molecule non-covalent SARS-CoV-2 Mpro inhibitor with IC50 of 1.0 uM.

Y180 is a highly potent, selective, covalent, and orally active SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 8.1 nM in enzymatic assays, binding Ki value of 1 nM.

WU-04 is a highly potent, non-covalent, orally active inhibitor of SARS-CoV-2 3C-like protease (3CLpro) with IC50 of 72 nM, binding Kd of 37 nM.

WNN2048-F004 (Compound 4a) is a potent, covalent, nonpeptidomimetic SARS-CoV-2 main protease (Mpro) inhibitor with biochemical IC50 of 103 nM, covalently binds to the substrate-binding pocket (Cys145) of SARS-CoV-2 Mpro.

VE607 is a specific small molecule inhibitor that block S protein-ACE2-mediated cellular entry of the SARS-CoV, inhibits pseudovirus entry with EC50 of 3 μM and inhibited SARS-CoV plaque formation with EC50 of 1.6 μM.

TKB248 (TKB-248) is a potent, specific SARS-CoV-2 Mpro inhibitor with IC50 of 74 nM, exhibits highly potent anti-SARS-CoV-2 activity with EC50 and EC95 values of 0.22 and 0.87 µM, respectively.

TKB245 (TKB-245) is a potent, specific SARS-CoV-2 Mpro inhibitor with IC50 of 7 nM, exhibits highly potent anti-SARS-CoV-2 activity with EC50 and EC95 values of 0.03 and 0.53 µM, respectively.

Titanocene dichloride (Cp2 TiCl 2) is an active inhibitor of interaction between SARS-CoV-2 spike (S) protein with the ACE2 receptor (IC50=3.9 uM)

Simnotrelvir (SSD8432, SIM0417) is a potent, selective, covalent and orally bioavailable SARS-CoV-2 3C-like protease (3CLpro) inhibitor with IC50 of 9 nM in enzymatic inhibition assays.

SCoV2 Plpro-Probe-7 is a peptidomimetic activity probe and substrate for SCoV2 PLpro, exhibits excellent sensitivity to wild-type (WT) SCoV2 PLpro, but not to the catalytically inactive mutant, SCoV2 PLproC112S, consists of a fluorogenic HCC conjugated to

Pomotrelvir (PBI-0451) is a potent competitive inhibitor of SARS-CoV-2 Mpro (Ki=2.7 nM) with high selectivity against human proteases, inhibits wild-type SARS-CoV-2 Mpro with IC50 of 24 nM.

PAV-104 (PAV104) is a novel viral assembly inhibitor, shows potent anti-SARS-CoV-2 activity in Calu-3 cells with EC50 of 1.7 nM and EC90 of 23.5 nM, inhibits the oligomerization of the SARS-CoV-2 nucleocapsid.

P2165 (P-2165) is a anticoronaviruse chemical probe that inhibit SARS-CoV-2 Spike binding to human ACE2 receptor.

P2119 (P-2119) is an anticoronaviruse chemical probe that inhibit SARS-CoV-2 Spike binding to human ACE2 receptor.

Olgotrelvir (STI-1558) is a next-generation antiviral targeting SARS-CoV-2 Mpro and host lysosomal cysteine protease cathepsin L (CTSL) with high antiviral activity, Olgotrelvir is the prodrug of AC1115.

NSC 621601 (Compound Q34) is a potent, specific inhibitor of SARS-CoV-2 cellular entry with IC50 of 15 uM.

NBCoV1 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=17 nM, SARS-CoV-2 IC50=51 nM, MERS-CoV IC50=75 nM, cell-based single-cycle assays).

MU-UNMC-2 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 1.72 uM in human bronchial epithelial cells.

MU-UNMC-1 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 0.67 uM in human bronchial epithelial cells.

MPI8 is a highly potent SARS-CoV-2 main protease (MPro) inhibitor with IC50 of 33 nM, completely prevented the SARS-CoV-2-induced cytopathogenic effect in Vero E6 cells at 2.5-5 uM and A549 cells at 0.16-0.31 uM.

MPI8 is a highly potent SARS-CoV-2 main protease (MPro) inhibitor with IC50 of 8.5 nM.